For this reason, a selective BCL-2 inhibitor ABT-199, also known as venetoclax, was generated next and proven to be effective predominantly in the subgroup of MM patients harboring the t(11;14) translocation [19]. The gene discussed is BCL2; the disease is Miyoshi myopathy.